Profound Medical reported a larger quarterly loss than analysts expected. It has now missed estimates in two of its last four reported quarters.
Profound Medical Corp (TSX: PRN) reported fiscal third-quarter 2026 results after markets closed on November 5. The company posted a loss of C$0.29 per share, compared with analysts’ expected loss of C$0.27, a 7.4% miss. Profound develops MRI-guided systems for incision-free tissue ablation, including treatments for prostate and other tumours. The company is still loss-making, with trailing-twelve-month EPS of -C$1.37 and a profit margin of -171.56%.
Recent earnings trend
Profound Medical Corp
PRN.TO
PRN.TO
Profound Medical Corp
WealthAwesomeMarket cap
$370.52M
52W high
$12.40
52W low
$6.52
1W change
+10.46%
Beta
0.56
Analyst Price Targets
Based on analyst covering PRN · as of Sep 17, 2026
Wall Street analysts forecast PRN stock price to rise 146.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.03
+146.8% Upside
Current Price
C$10.14
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PRN's historical volatility
30-Day Vol
79.8%
Annualized
90-Day Vol
66.4%
Annualized
Trend (90d)
+17.8%
Annualized drift
90d Mean
C$10.80
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.36 | C$7.86 – C$13.64 |
| 60 trading days | C$10.58 | C$7.17 – C$15.61 |
| 90 trading days | C$10.80 | C$6.71 – C$17.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 4 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-03-04 | — | -0.2700 | — |
| 2026-09-30 | 2026-11-05 | -0.2900 | -0.2700 | -7.4% |
| 2026-06-30 | 2026-08-06 | -0.3600 | -0.3400 | -5.9% |
| 2026-03-31 | 2026-05-07 | -0.2600 | -0.3500 | +25.7% |
| 2025-12-31 | 2026-03-05 | -0.3700 | -0.3800 | +2.6% |
| 2025-09-30 | 2025-11-13 | -0.3600 | -0.5200 | +30.8% |
Investor takeaway: The miss was modest, but it followed another quarterly miss after a 25.7% beat in March. Investors considering the long-term potential of Profound’s MRI-guided systems should also weigh its ongoing losses and the uncertainty around how quickly sales can grow. See the PRN stock page for more company details.
C$0.29 loss per share
Profound’s loss of C$0.29 per share was 7.4% larger than the C$0.27 loss analysts expected. The company has beaten estimates in two of its last four reported quarters. The recent-earnings table shows the results for each quarter.
Bull case
Profound is developing image-guided systems for incision-free treatments. Recent company coverage has highlighted U.S. distribution agreements, software upgrades and imaging partnerships. For the upcoming quarter, analysts expect revenue to grow 22.4% year over year to C$9.07 million and the loss to narrow from a year earlier. The share price also closed above its 50-day and 200-day moving averages. These factors may support the growth case, but they don’t guarantee profitability or broad adoption.
Bear case
Profound remains deeply unprofitable, with a -171.56% profit margin and trailing EPS of -C$1.37. It missed EPS estimates in both the June and September quarters. Analysts also lowered their upcoming-quarter EPS forecast over the past 30 days, from a loss of C$0.33 to C$0.34. Growth in the medical-equipment market won’t remove the company’s execution risks. Investors still need to see revenue growth lead to better margins and a more sustainable financial position.
Analysis
For the quarter ended September 30, Profound reported a loss of C$0.29 per share, compared with the expected loss of C$0.27. That was a 7.4% miss, following a loss of C$0.36 against an expected C$0.34 in the June quarter. Before those two misses, the company beat estimates by 25.7% in March and 2.6% in December. It has beaten estimates in two of its last four reported quarters.
The supplied results don’t include actual revenue or margin figures for the quarter, so EPS is the clearest measure available. The company’s broader financial snapshot remains weak, with trailing EPS of -C$1.37 and a profit margin of -171.56%.
Analysis
For the quarter ending December 31, analysts expect a loss of C$0.34 per share. Estimates from four analysts range from -C$0.32 to -C$0.37. The expected loss is smaller than the year-ago loss of C$0.36, with estimated EPS growth of 7.8%. Analysts expect revenue of C$9.07 million, up 22.4% year over year.
EPS expectations have edged down over the past 30 days, from a loss of C$0.33 to C$0.34. One analyst lowered their estimate, and none raised theirs. These are forecasts, not reported results. Profound’s MRI-guided systems and commercial initiatives provide business context, but the available information doesn’t show how quickly they will increase adoption or improve profitability.
Analysis
Analysts’ average price target is C$25.03, compared with the last close of C$10.14. That implies 146.8% upside to the average target. The supplied data describe the consensus as bullish based on the target-price comparison. A formal rating isn’t available for Canadian listings. Price targets are estimates, not guaranteed outcomes. See the analyst ratings section for details.
Analysis
Wealth Awesome’s statistical 90-day model gives a mean forecast of C$10.80, compared with the C$10.14 reference price on November 6. The model’s 68% range is C$6.71 to C$17.40, and its 95% range is C$4.16 to C$28.04. The wide ranges and stated 79.8% 30-day volatility point to substantial uncertainty. This is a statistical model, not financial advice or a price target. See the price-prediction section for details.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
